• OPEN AN ACCOUNT
Indian Indices
Nifty
25,492.30 -17.40
(-0.07%)
Sensex
83,216.28 -94.73
( -0.11%)
Bank Nifty
57,876.80 322.55
( 0.56%)
Nifty IT
35,117.65 -219.95
( -0.62%)
Global Indices
Nasdaq
46,931.02 -400.98
(-0.85%)
Dow Jones
6,741.06 -76.23
(-1.12%)
Hang Seng
50,211.07 -672.61
(-1.32%)
Nikkei 225
9,688.02 -47.76
(-0.49%)
Forex
USD-INR
88.65 -0.03
(-0.04%)
EUR-INR
101.82 -0.15
(-0.14%)
GBP-INR
115.54 -0.38
(-0.33%)
JPY-INR
0.58 0.00
(-0.08%)

EQUITY - MARKET SCREENER

Shukra Pharmaceuticals Ltd
Industry :  Pharmaceuticals - Indian - Formulations
BSE Code
ISIN Demat
Book Value()
524632
INE551C01044
1.4350033
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
N.A
174.65
1758.96
EPS(TTM)
Face Value()
Div & Yield %
0.23
1
0.02
 

hindustan unilever ltd
NDA Securities Ltd - Board Meeting Outcome for Disclosure In Compliance With Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Outcome Of Board Meeting
Jun 10,2025
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (LODR Regulations) we wish to inform you that the Board of Directors of NDA Securities Limited at its meeting held today Tuesday June 10 2025 has inter-alia considered and approved the following matters: 1. Approval for Investment in NDA Research and Technologies Private Limited to make it a Wholly Owned Subsidiary: 2. Shifting of Corporate Office. This is for your information and record.